The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

WCLC 2022 | The macrophage migration inhibitory factor (MIF) as a therapeutic and diagnostic target

Name: The macrophage migration inhibitory factor (MIF) as a therapeutic and diagnostic target
Uploaded: 2022-08-07T00:00:00Z
Duration: 1 min 2 s
Description: Christine Landlinger-Schubert, PhD, OncoOne, Klosterneuburg, Austria, talks on the macrophage migration inhibitory factor (MIF) as a target for the treatment of both solid tumors and chronic inflammatory diseases, as well as a diagnostic tool. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.

Christine Landlinger-Schubert • 7 Aug 2022

WCLC 2022

Lung Cancer Antibodies ON203

Christine Landlinger-Schubert, PhD, OncoOne, Klosterneuburg, Austria, talks on the macrophage migration inhibitory factor (MIF) as a target for the treatment of both solid tumors and chronic inflammatory diseases, as well as a diagnostic tool. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.